COMPARATIVE MARKET INTELLIGENCE · JUNE 2026 · UKMC GROUP LTD
The definitive investor-focused comparison of the two most active European medical cannabis markets — covering market size, regulatory environment, telemedicine risk, supply chain economics, investor activity and where risk-adjusted returns are most compelling in 2026 and 2027.
Published for informational purposes only. Does not constitute financial, legal, investment or regulatory advice. All data sourced from primary regulatory, corporate and verified press sources. Readers should seek independent professional advice before making any investment decision.
THE DATA
| Metric | Germany | United Kingdom |
|---|---|---|
| 2025 Market Size | €864 million (US $997 million) | £226 million (US $298 million) |
| 2025 Patient Count | 600,000–800,000 | 90,000–94,000 |
| Year-on-Year Growth | 155% | 103% |
| Unique SKUs Available | 1,752 | 628 |
| Average Flower Price | €7.20/g | £7.05/g |
| Import Dependency (2025) | 98.8% | 96.9% (2024) |
| Teleclinics Identified | 35 | 29 |
| Top 5 Clinics Traffic (Oct 2025) | 4.2 million visits | 1.1 million visits |
Source: Prohibition Partners Global Medical Cannabis Market Review 2026. Germany data: BfArM, INCB, Prohibition Partners. UK data: Home Office, MedBud.wiki, Prohibition Partners. SimilarWeb October 2025.
REGULATORY COMPARISON
The Germany and UK medical cannabis markets look similar on the surface — both European, both growing rapidly, both heavily import-dependent, both driven by private prescription and telemedicine. But their regulatory architectures are fundamentally different in ways that directly determine investment risk profiles.
Since 1 April 2024, medical cannabis is no longer classified as a narcotic under the German Narcotic Drugs Act (BtMG). Any doctor in Germany can now prescribe medical cannabis using a standard or electronic prescription, just as they would with any other off-label medication. There is no peer review requirement. No specialist-only restriction. No requirement for conventional treatment failure. This near-unrestricted prescribing model drove the 155% market growth in 2025 — but it also triggered the regulatory backlash now working through the Bundestag. The Federal Cabinet approved proposed MedCanG amendments on 8 October 2025, mandating mandatory in-person initial consultations, limiting remote repeat prescriptions and banning mail-order pharmacies. The Bundestag held its first reading on 18 December 2025. Further readings and a vote are expected in spring 2026. As of the Cannabis Europa London 2026 conference (26–27 May 2026), the legislative process remained ongoing — described by speakers as "near silence" since the December 2025 first reading.
Source: Prohibition Partners 2026; BfArM; Cannabis Europa London 2026 Day 2 report, Business of Cannabis May 2026.
UK medical cannabis remains restricted to specialist prescribing only. GPs cannot prescribe CBPMs. Many clinics require peer review before issuance. CQC registration is mandatory for all prescribing services. GPhC authorisation is mandatory for all dispensing pharmacies. The ACMD review — commissioned June 2025, evidence period closed October 2025 — is assessing whether the framework needs reform, but no legislative changes have been proposed or enacted as of June 2026. Mail-order pharmacy delivery remains legal and unrestricted in the UK — a structural advantage over Germany's proposed mail-order ban.
TELEMEDICINE RISK
This is the most important investment risk comparison between the two markets in 2026.
RISK RATING
Telemedicine has been the engine of Germany's post-CanG growth — driving patient numbers and the 200-plus tonnes of imports recorded in 2025. Yet Germany is actively attempting to restrict it. The proposed MedCanG amendments mandate mandatory in-person initial consultations and ban mail-order pharmacy delivery. Kristine Lütke, former member of the Bundestag and one of the architects of the original medical cannabis legislation, stated at Cannabis Europa London 2026: restricting telemedicine and flower delivery will not have a positive effect on public health — people will return to the illicit market. Sascha Mielcarek, CEO of Canify, described the political reality at the same event as uncertain, noting that since the December 2025 first reading there had been near silence on legislative progress. Prohibition Partners' three-scenario market model projects: under Some Restrictions — a 25% market decline in 2026, with patient numbers falling from 700,000 to 560,000 before recovering; under All Restrictions — a 50% patient decline, from 700,000 to 430,000, with recovery at 40% of the Some Restrictions rate.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026; Business of Cannabis, Cannabis Europa London 2026 Day 2, May 2026.
RISK RATING
The UK's telemedicine framework is currently unchallenged by legislation. No draft bill to restrict medical cannabis telemedicine has been introduced as of June 2026. The ACMD review could recommend changes — but the review process can take up to a year or longer until final recommendations are made and implemented. The UK's existing regulatory requirements (specialist-only prescribing, CQC oversight, peer review at many clinics) already embed a degree of clinical oversight that Germany's pre-amendment framework lacked — which may make regulators more cautious about introducing additional restrictions. The Poland precedent — 54% prescription decline in two months following November 2024 telemedicine restrictions, followed by recovery within two quarters — is being monitored closely by UK policymakers.
Source: Prohibition Partners 2026; ACMD review timeline.
SUPPLY CHAIN
Both markets are heavily import-dependent and subject to the same global supply chain dynamics. Canada exported 275,343 kilograms of medical cannabis in 2025 — more than 2.5 times the 2024 volume — creating significant global price pressure. German bulk flower prices have collapsed to €1–€2 per gram for GACP-certified product, while EU-GMP certified flower still commands a premium. Source: Business of Cannabis March 2026.
In 2025, Germany imported 98.8% of its medical cannabis, with only 1.2% domestically cultivated. The total import volume in 2025 exceeded 50 tonnes in Q1 2026 alone — confirming Germany's position as the dominant European import market. The top suppliers are Canada, Portugal, Denmark, North Macedonia and Spain. The primary product format is flower (86.8%), with oil accounting for 13.2%.
Source: BfArM, INCB, Prohibition Partners 2026.
In 2024, the UK imported 96.9% of its medical cannabis, with 3.1% domestically cultivated — by four companies: Dalgety, Glass Pharms, Celadon and Northern Leaf. The UK imported approximately 15.5 tonnes in 2024 and the 2025 import volume is confirmed to be significantly higher. Primary suppliers to the UK are Canada, Spain and Portugal. The primary format is flower (77.1%), with oil (17.5%) and vapes (5.1%) making up the remainder.
Source: Home Office, Prohibition Partners 2026.
"The most active segment for European cannabis investment in 2026 is pharmaceutical-grade medical cannabis operators with demonstrated revenue on the German and UK markets. Germany's prescription volume makes it the dominant revenue pool; the UK CBPM market represents a high-margin complementary geography."
— Cannabis Europa, April 2026
INVESTOR ACTIVITY
Family offices and private equity firms are targeting asset-light, profitable companies for M&A — with those at the top of the acquisition target list being operators with well-established pharmacy and prescriber relationships, extensive patient behaviour data and a trusted reputation. The inherent regulatory uncertainty associated with the industry is impacting valuations while driving risk-sharing deal structures.
Source: Business of Cannabis.
M&A is accelerating in Germany as price compression erodes sub-scale operator margins. Canadian licensed producers are restructuring European exposure — creating acquisition opportunities for emerging European consolidators. German bulk flower prices have collapsed to €1–€2 per gram for GACP product, while EU-GMP certified flower still commands a premium. The German Federal Court of Justice ruling of 26 March 2026 (I ZR 74/25) has introduced new compliance considerations for M&A transaction structuring. Private equity focused on consolidation plays is typically targeting companies with revenues above €5 million and a clear path to market leadership in a specific geography or product category.
Source: Cannabis Europa.
The UK clinic market has seen Mamedica's £4.5 million Casa Verde round (September 2025), Releaf's continued growth to £38 million revenue and 25,000+ patients (March 2026), and Tilray's strategic acquisition of Lyphe creating Tilray Lyphe UK Ltd. Family offices are the most consistent source of patient European cannabis capital according to Cannabis Europa's 2026 investment analysis.
THE COMBINED THESIS
Investor interest focuses on operators that own or control their distribution relationships rather than relying on wholesaler intermediaries, and on those with formulary presence — consistent CBPM prescribing driven by physician familiarity and clinical data rather than promotional spend. Source: Cannabis Europa.
INVESTOR VERDICT
This is not a binary choice — the optimal European medical cannabis investment thesis in 2026 combines exposure to both markets. But the risk-adjusted comparison is instructive.
VERDICT
Germany's market is four times larger than the UK's by value and has eight times as many patients. The growth trajectory is steeper. But the near-term regulatory risk from MedCanG amendments is acute and material — the three-scenario Prohibition Partners model ranges from a 25% market decline to a 50% patient loss depending on the final legislative outcome. Investors entering the German market in H1 2026 are taking on telemedicine restriction risk that has not yet been resolved. The appropriate investor type is patient capital with a three to five year horizon, comfortable with a potential 12–18 month contraction period before recovery.
VERDICT
The UK market is smaller but growing at 103% year-on-year from a lower base. The regulatory framework is already more restrictive than Germany's pre-amendment model — which paradoxically makes it less exposed to the acute regulatory correction risk Germany now faces. The ACMD review is a risk, but no legislative proposals have been introduced and the review process will take months to years to complete. Mail-order pharmacy delivery remains unrestricted. Specialist-only prescribing and CQC oversight are already embedded. The UK market is more appropriate for investors seeking a lower-volatility European medical cannabis entry with a cleaner near-term regulatory horizon.
THE COMBINED VIEW
Active capital flows into EU-GMP certified cultivation and manufacturing infrastructure, medical cannabis distribution in Germany and the UK, and ancillary services — particularly compliance technology and specialist banking solutions. The investors doing best in European cannabis in 2026 built their thesis on the medical market alone — not on adult-use speculation. That thesis applies to both Germany and the UK.
Source: Cannabis Europa.
THE SUMMIT
The UK Medical Cannabis Investment Summit 2027 brings together operators, investors, family offices, policymakers and clinicians from across Germany, the UK and the wider European market. Two days. London. June 2027.
FREQUENTLY ASKED QUESTIONS
IMPORTANT NOTICE: This page is published by UKMC Group Ltd for informational purposes only. Nothing on this page constitutes financial, investment, legal or regulatory advice. All data is sourced from primary regulatory, corporate and verified press sources as cited throughout. Market and regulatory conditions change — readers should verify current information independently and seek qualified professional advice before making any investment decision. © 2026 UKMC Group Ltd.